The FDA issued an Early Communication regarding its ongoing review of Vytorin (ezetimibe and simvastatin) based on preliminary results from the recently completed ENHANCE (Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) study on this cholesterol-lowering drug.